$517 Million is the total value of Artia Global Partners LP's 46 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 46.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVO | NOVO-NORDISK A Sadr | $98,739,396 | +11.2% | 691,743 | 0.0% | 19.09% | +6.9% | |
| LLY | ELI LILLY & CO | $83,831,850 | +16.4% | 92,593 | 0.0% | 16.20% | +11.9% | |
| Sell | ELI LILLY & COput | $67,903,500 | -24.1% | 75,000 | -34.8% | 13.13% | -27.0% | |
| MRK | Buy | MERCK & CO INC | $54,781,995 | +9.5% | 442,504 | +16.7% | 10.59% | +5.3% |
| New | NOVO-NORDISK A Sput | $44,249,400 | – | 310,000 | +100.0% | 8.55% | – | |
| VKTX | Buy | VIKING THERAPEUTICS INC | $24,012,417 | -32.5% | 452,979 | +4.5% | 4.64% | -35.0% |
| AZN | ASTRAZENECA PLCsponsored adr | $14,876,748 | +15.1% | 190,752 | 0.0% | 2.88% | +10.7% | |
| ITCI | Buy | INTRA-CELLULAR THERAPIES INC | $14,829,386 | +2.0% | 216,519 | +3.1% | 2.87% | -1.9% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $8,858,808 | -26.7% | 18,900 | -34.6% | 1.71% | -29.5% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $8,505,000 | – | 35,000 | +100.0% | 1.64% | – |
| New | VIKING THERAPEUTICS INCcall | $7,951,500 | – | 150,000 | +100.0% | 1.54% | – | |
| New | INSMED INCput | $7,370,000 | – | 110,000 | +100.0% | 1.42% | – | |
| AXSM | AXSOME THERAPEUTICS INC | $7,071,764 | +0.9% | 87,848 | 0.0% | 1.37% | -3.0% | |
| ARGX | Sell | ARGENX SEsponsored adr | $6,509,946 | -51.7% | 15,138 | -55.8% | 1.26% | -53.6% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $6,195,150 | -0.2% | 45,000 | 0.0% | 1.20% | -3.9% | |
| PCVX | VAXCYTE INC | $5,758,015 | +10.5% | 76,255 | 0.0% | 1.11% | +6.3% | |
| PTGX | PROTAGONIST THERAPEUTICS INC | $4,311,846 | +19.8% | 124,440 | 0.0% | 0.83% | +15.1% | |
| DYN | DYNE THERAPEUTICS INC | $4,216,732 | +24.3% | 119,488 | 0.0% | 0.82% | +19.5% | |
| Buy | SOLENO THERAPEUTICS INC | $3,852,499 | +119.9% | 94,424 | +130.7% | 0.74% | +111.6% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $3,841,414 | -4.3% | 85,765 | 0.0% | 0.74% | -7.9% | |
| INSM | Sell | INSMED INC | $3,580,212 | +11.6% | 53,436 | -54.8% | 0.69% | +7.3% |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $3,420,000 | -48.1% | 500,000 | -31.0% | 0.66% | -50.2% |
| IONS | New | IONIS PHARMACEUTICALS INC | $2,977,749 | – | 62,479 | +100.0% | 0.58% | – |
| MRUS | MERUS N V | $2,968,618 | +31.4% | 50,171 | 0.0% | 0.57% | +26.4% | |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $2,786,853 | – | 75,300 | +100.0% | 0.54% | – |
| Sell | APOGEE THERAPEUTICS INC | $2,298,040 | -43.8% | 58,400 | -5.2% | 0.44% | -46.1% | |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $2,031,543 | -23.5% | 53,930 | 0.0% | 0.39% | -26.4% | |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $1,909,703 | -17.1% | 54,392 | +3.6% | 0.37% | -20.3% |
| VRNA | VERONA PHARMA PLCsponsored ads | $1,891,223 | -10.1% | 130,790 | 0.0% | 0.37% | -13.5% | |
| XENE | XENON PHARMACEUTICALS INC | $1,559,600 | -9.4% | 40,000 | 0.0% | 0.30% | -13.0% | |
| MREO | MEREO BIOPHARMA GROUP PLCspon ads | $1,516,892 | +9.1% | 421,359 | 0.0% | 0.29% | +5.0% | |
| CRL | CHARLES RIV LABS INTL INC | $1,426,435 | -23.8% | 6,905 | 0.0% | 0.28% | -26.6% | |
| KURA | Buy | KURA ONCOLOGY INC | $1,177,295 | +39.8% | 57,178 | +44.8% | 0.23% | +34.9% |
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $1,042,815 | -18.8% | 54,285 | 0.0% | 0.20% | -21.7% | ||
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $1,014,667 | -57.8% | 7,440 | -53.2% | 0.20% | -59.4% |
| SLN | SILENCE THERAPEUTICS PLCads | $997,044 | -12.0% | 52,476 | 0.0% | 0.19% | -15.4% | |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $990,839 | – | 48,263 | +100.0% | 0.19% | – |
| KROS | New | KEROS THERAPEUTICS INC | $914,000 | – | 20,000 | +100.0% | 0.18% | – |
| New | CORBUS PHARMACEUTICALS HLDGS | $905,000 | – | 20,000 | +100.0% | 0.18% | – | |
| EYPT | Buy | EYEPOINT PHARMACEUTICALS INC | $883,050 | -17.0% | 101,500 | +97.1% | 0.17% | -20.1% |
| ANNX | ANNEXON INC | $722,677 | -31.7% | 147,485 | 0.0% | 0.14% | -34.3% | |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $656,053 | +48.5% | 90,490 | +55.5% | 0.13% | +42.7% |
| Sell | DISC MEDICINE INC | $605,741 | -88.8% | 13,440 | -84.6% | 0.12% | -89.3% | |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $537,500 | -63.9% | 50,000 | -50.0% | 0.10% | -65.2% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $436,209 | +4.9% | 1,557 | 0.0% | 0.08% | 0.0% | |
| SRPT | New | SAREPTA THERAPEUTICS INC | $410,800 | – | 2,600 | +100.0% | 0.08% | – |
| GRTS | Exit | GRITSTONE BIO INC | $0 | – | -95,170 | -100.0% | -0.05% | – |
| PSTX | Exit | POSEIDA THERAPEUTICS INC | $0 | – | -86,002 | -100.0% | -0.06% | – |
| Exit | EFFECTOR THERAPEUTICS INCcall | $0 | – | -25,000 | -100.0% | -0.07% | – | |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -35,452 | -100.0% | -0.11% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -21,397 | -100.0% | -0.14% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -64,007 | -100.0% | -0.19% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -24,298 | -100.0% | -0.21% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -137,308 | -100.0% | -0.25% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -40,000 | -100.0% | -0.33% | – |
| JANX | Exit | JANUX THERAPEUTICS INC | $0 | – | -47,949 | -100.0% | -0.36% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -51,714 | -100.0% | -0.41% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -89,525 | -100.0% | -1.26% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -90,821 | -100.0% | -3.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 7 | Q2 2024 | 25.8% |
| MERCK & CO INC | 7 | Q2 2024 | 14.1% |
| LILLY ELI & CO | 7 | Q2 2024 | 16.2% |
| ARGENX SE | 7 | Q2 2024 | 12.3% |
| ASTRAZENECA PLC | 7 | Q2 2024 | 5.4% |
| VIKING THERAPEUTICS INC | 7 | Q2 2024 | 7.1% |
| NEUROCRINE BIOSCIENCES INC | 7 | Q2 2024 | 2.1% |
| INTRA-CELLULAR THERAPIES INC | 7 | Q2 2024 | 2.9% |
| ABBVIE INC | 6 | Q1 2024 | 5.6% |
| VERTEX PHARMACEUTICALS INC | 6 | Q2 2024 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.